TrialJournal of neuro-oncology2015

Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma.

Seema Nagpal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.